AbCellera Biologics Inc.

NasdaqGS:ABCL Stock Report

Market Cap: US$1.1b

AbCellera Biologics Valuation

Is ABCL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of ABCL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate ABCL's future cash flow value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate ABCL's future cash flow value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ABCL?

Key metric: As ABCL is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ABCL. This is calculated by dividing ABCL's market cap by their current revenue.
What is ABCL's PS Ratio?
PS Ratio14x
SalesUS$75.13m
Market CapUS$1.11b

Price to Sales Ratio vs Peers

How does ABCL's PS Ratio compare to its peers?

The above table shows the PS ratio for ABCL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.4x
MRVI Maravai LifeSciences Holdings
2.6x7.47%US$912.6m
BLFS BioLife Solutions
9.1x17.17%US$918.2m
AZTA Azenta
1.7x5.86%US$1.1b
FTRE Fortrea Holdings
0.3x2.24%US$880.8m
ABCL AbCellera Biologics
14x10.74%US$1.1b

Price-To-Sales vs Peers: ABCL is expensive based on its Price-To-Sales Ratio (14x) compared to the peer average (3.4x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does ABCL's PS Ratio compare vs other companies in the US Life Sciences Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
FTRE Fortrea Holdings
0.3x2.24%US$880.77m
HBIO Harvard Bioscience
0.2x1.34%US$22.40m
NOTV Inotiv
0.03x5.22%US$13.42m
BNGO Bionano Genomics
0.4x21.70%US$11.70m
ABCL 14.0xIndustry Avg. 2.7xNo. of Companies8PS0246810+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ABCL is expensive based on its Price-To-Sales Ratio (14x) compared to the US Life Sciences industry average (2.7x).

Price to Sales Ratio vs Fair Ratio

What is ABCL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ABCL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio14x
Fair PS Ratio0.3x

Price-To-Sales vs Fair Ratio: ABCL is expensive based on its Price-To-Sales Ratio (14x) compared to the estimated Fair Price-To-Sales Ratio (0.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ABCL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$3.47
US$9.17
+164.17%
19.33%US$12.00US$7.00n/a6
Mar ’27US$3.61
US$9.17
+153.92%
19.33%US$12.00US$7.00n/a6
Feb ’27US$3.62
US$9.83
+171.64%
30.74%US$16.00US$7.00n/a6
Jan ’27US$3.42
US$9.83
+187.52%
30.74%US$16.00US$7.00n/a6
Dec ’26US$3.47
US$9.83
+183.38%
30.74%US$16.00US$7.00n/a6
Nov ’26US$5.55
US$9.33
+68.17%
41.34%US$17.00US$5.00n/a6
Oct ’26US$5.96
US$9.33
+56.60%
41.34%US$17.00US$5.00n/a6
Sep ’26US$4.18
US$9.29
+122.15%
38.49%US$17.00US$5.00n/a7
Aug ’26US$4.24
US$9.14
+115.63%
41.10%US$17.00US$5.00n/a7
Jul ’26US$3.49
US$8.43
+141.51%
47.40%US$17.00US$5.00n/a7
Jun ’26US$2.02
US$8.43
+317.26%
47.40%US$17.00US$5.00n/a7
May ’26US$2.49
US$11.71
+370.45%
70.65%US$28.00US$5.00n/a7
Apr ’26US$2.09
US$11.86
+467.33%
69.17%US$28.00US$4.00n/a7
Mar ’26US$2.59
US$11.86
+358.69%
69.17%US$28.00US$4.00US$3.617
Feb ’26US$3.17
US$12.14
+283.06%
67.25%US$28.00US$4.00US$3.627
Jan ’26US$2.93
US$12.29
+319.31%
65.36%US$28.00US$5.00US$3.427
Dec ’25US$3.01
US$12.29
+308.16%
65.36%US$28.00US$5.00US$3.477
Nov ’25US$2.73
US$14.00
+412.82%
51.08%US$28.00US$5.00US$5.557
Oct ’25US$2.57
US$14.00
+444.75%
51.08%US$28.00US$5.00US$5.967
Sep ’25US$2.56
US$14.00
+446.88%
51.08%US$28.00US$5.00US$4.187
Aug ’25US$3.05
US$14.38
+371.31%
47.05%US$28.00US$5.00US$4.248
Jul ’25US$2.78
US$14.63
+426.08%
44.04%US$28.00US$7.00US$3.498
Jun ’25US$3.92
US$14.63
+273.09%
44.04%US$28.00US$7.00US$2.028
May ’25US$3.78
US$14.75
+290.21%
42.71%US$28.00US$8.00US$2.498
Apr ’25US$4.44
US$14.75
+232.21%
42.71%US$28.00US$8.00US$2.098
Mar ’25US$5.05
US$14.75
+192.08%
42.71%US$28.00US$8.00US$2.598
US$9.17
Fair Value
62.1% undervalued intrinsic discount
6
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/12 11:17
End of Day Share Price 2026/03/12 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AbCellera Biologics Inc. is covered by 16 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert WassermanBenchmark Company
Antonia BorovinaBloom Burton & Co.
David MartinBloom Burton & Co.